# MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

> **NCT03778619** · PHASE1,PHASE2 · UNKNOWN · sponsor: **GC Cell Corporation** · enrollment: 9 (actual)

## Conditions studied

- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** MG4101(allogeneic Natural Killer cell)
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03778619
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-28
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-10-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778619, "MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03778619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*